AR102781A1 - Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos - Google Patents
Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usosInfo
- Publication number
- AR102781A1 AR102781A1 ARP150103849A ARP150103849A AR102781A1 AR 102781 A1 AR102781 A1 AR 102781A1 AR P150103849 A ARP150103849 A AR P150103849A AR P150103849 A ARP150103849 A AR P150103849A AR 102781 A1 AR102781 A1 AR 102781A1
- Authority
- AR
- Argentina
- Prior art keywords
- nanoparticles
- compound
- biocompatible
- pharmaceutical composition
- interest
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title abstract 19
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 abstract 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 2
- 229910000019 calcium carbonate Inorganic materials 0.000 abstract 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 abstract 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052710 silicon Inorganic materials 0.000 abstract 2
- 239000010703 silicon Substances 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- CUPCBVUMRUSXIU-UHFFFAOYSA-N [Fe].OOO Chemical compound [Fe].OOO CUPCBVUMRUSXIU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- FAHBNUUHRFUEAI-UHFFFAOYSA-M hydroxidooxidoaluminium Chemical compound O[Al]=O FAHBNUUHRFUEAI-UHFFFAOYSA-M 0.000 abstract 1
- 229910010272 inorganic material Inorganic materials 0.000 abstract 1
- 239000011147 inorganic material Substances 0.000 abstract 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 abstract 1
- 229910021519 iron(III) oxide-hydroxide Inorganic materials 0.000 abstract 1
- HDMKAUUMGFGBRJ-UHFFFAOYSA-N iron;dihydrate Chemical compound O.O.[Fe] HDMKAUUMGFGBRJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 abstract 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 abstract 1
- 239000000347 magnesium hydroxide Substances 0.000 abstract 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306874 | 2014-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102781A1 true AR102781A1 (es) | 2017-03-22 |
Family
ID=52013981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103849A AR102781A1 (es) | 2014-11-25 | 2015-11-24 | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10391058B2 (enExample) |
| EP (1) | EP3229776B1 (enExample) |
| JP (1) | JP6836510B2 (enExample) |
| AR (1) | AR102781A1 (enExample) |
| DK (1) | DK3229776T3 (enExample) |
| ES (1) | ES2951598T3 (enExample) |
| FI (1) | FI3229776T3 (enExample) |
| HU (1) | HUE062561T2 (enExample) |
| LT (1) | LT3229776T (enExample) |
| PL (1) | PL3229776T3 (enExample) |
| PT (1) | PT3229776T (enExample) |
| TW (1) | TW201628654A (enExample) |
| WO (1) | WO2016083343A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014191569A1 (en) | 2013-05-30 | 2014-12-04 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| ES2774365T3 (es) | 2014-11-25 | 2020-07-20 | Curadigm Sas | Composición farmacéutica, preparación y usos de la misma |
| UA123665C2 (uk) * | 2014-11-25 | 2021-05-12 | Кюрадігм Сас | Фармацевтична композиція, її одержання і застосування |
| EP3229776B1 (en) * | 2014-11-25 | 2023-06-28 | Curadigm Sas | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
| EP3223796B1 (en) | 2014-11-25 | 2021-07-21 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
| UA124572C2 (uk) | 2015-05-28 | 2021-10-13 | Нанобіотікс | Наночастинки для застосування як терапевтичної вакцини |
| CN115137822B (zh) * | 2022-06-13 | 2023-06-23 | 武汉大学中南医院 | 一种光热热电一体化的抗肿瘤植入体的制备方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| US6160006A (en) | 1996-10-18 | 2000-12-12 | Wayne State University | 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit |
| JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
| DE69819519T2 (de) | 1997-08-19 | 2004-09-23 | Warner-Lambert Co. Llc | Bergamottin enthaltende zusammensetzungen zur erhöhung der oralen bioverfügbarkeit von pharmazeutika |
| US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| JP2004501955A (ja) * | 2000-06-30 | 2004-01-22 | アイネックス ファーマシューティカルズ コーポレイション | リポソーム抗新生物薬剤およびその使用 |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| US20050090732A1 (en) | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| CA2547024C (en) | 2003-12-22 | 2013-12-17 | Bracco Research Sa | Gas-filled microvesicle assembly for contrast imaging |
| US20080193372A1 (en) * | 2004-02-10 | 2008-08-14 | Barnes-Jewish Hospital | Efficacy and Safety of Targeted Particulate Agents with Decoy Systems |
| US20060264804A1 (en) | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
| WO2006127962A2 (en) * | 2005-05-25 | 2006-11-30 | Becton, Dickinson And Comapny | Particulate formulations for intradermal delivery of biologically active agents |
| DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| WO2007122956A1 (ja) | 2006-03-24 | 2007-11-01 | Toto Ltd. | 酸化チタン複合体粒子、その分散液、およびそれらの製造方法 |
| JP2009536151A (ja) | 2006-03-30 | 2009-10-08 | 富士フイルム株式会社 | ナノ粒子 |
| EP1852107A1 (en) | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
| WO2007128066A1 (en) | 2006-05-04 | 2007-11-15 | University Of South Australia | Drug release from nanoparticle-coated capsules |
| CA2697042A1 (en) | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| WO2009081287A2 (en) | 2007-12-21 | 2009-07-02 | University Of Guelph | Polysaccharide nanoparticles |
| US9403789B2 (en) | 2008-02-21 | 2016-08-02 | Sequoia Pharmaceuticals, Inc. | Benzofuran-containing amino acid inhibitors of cytochrome P450 |
| WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| WO2010048623A2 (en) | 2008-10-26 | 2010-04-29 | Board Of Regents, The University Of Texas Systems | Medical and imaging nanoclusters |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| US8580312B2 (en) | 2010-02-17 | 2013-11-12 | National University Corporation Kobe University | Radiation therapy agent |
| NZ602382A (en) | 2010-03-26 | 2014-11-28 | Abraxis Bioscience Llc | Methods of treatment of hepatocellular carcinoma |
| GB201009455D0 (en) | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| US9782342B2 (en) | 2010-10-11 | 2017-10-10 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| AU2011343664B2 (en) | 2010-12-17 | 2015-10-08 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA |
| WO2012104275A2 (en) | 2011-01-31 | 2012-08-09 | Nanobiotix | Nanoparticles delivery systems, preparation and uses thereof |
| EP2670393B8 (en) | 2011-01-31 | 2016-10-05 | Nanobiotix | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles. |
| WO2013059295A2 (en) | 2011-10-17 | 2013-04-25 | Trustees Of Boston University | Polymeric depots for localization of an agent to biological sites |
| CN102532154B (zh) | 2012-01-11 | 2014-05-14 | 昆明医学院 | 隆萼当归线型呋喃香豆素化合物及其应用 |
| US20150209397A1 (en) | 2012-09-07 | 2015-07-30 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| WO2014191569A1 (en) * | 2013-05-30 | 2014-12-04 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| SG11201704143YA (en) | 2014-11-25 | 2017-06-29 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| UA123665C2 (uk) | 2014-11-25 | 2021-05-12 | Кюрадігм Сас | Фармацевтична композиція, її одержання і застосування |
| EP3229776B1 (en) * | 2014-11-25 | 2023-06-28 | Curadigm Sas | Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof |
| EP3223796B1 (en) | 2014-11-25 | 2021-07-21 | Curadigm Sas | Pharmaceutical compositions, preparation and uses thereof |
| ES2774365T3 (es) | 2014-11-25 | 2020-07-20 | Curadigm Sas | Composición farmacéutica, preparación y usos de la misma |
-
2015
- 2015-11-24 EP EP15800777.3A patent/EP3229776B1/en active Active
- 2015-11-24 TW TW104139005A patent/TW201628654A/zh unknown
- 2015-11-24 ES ES15800777T patent/ES2951598T3/es active Active
- 2015-11-24 JP JP2017546034A patent/JP6836510B2/ja active Active
- 2015-11-24 FI FIEP15800777.3T patent/FI3229776T3/fi active
- 2015-11-24 WO PCT/EP2015/077446 patent/WO2016083343A1/en not_active Ceased
- 2015-11-24 LT LTEPPCT/EP2015/077446T patent/LT3229776T/lt unknown
- 2015-11-24 US US15/529,101 patent/US10391058B2/en active Active
- 2015-11-24 PL PL15800777.3T patent/PL3229776T3/pl unknown
- 2015-11-24 HU HUE15800777A patent/HUE062561T2/hu unknown
- 2015-11-24 AR ARP150103849A patent/AR102781A1/es unknown
- 2015-11-24 DK DK15800777.3T patent/DK3229776T3/da active
- 2015-11-24 PT PT158007773T patent/PT3229776T/pt unknown
-
2019
- 2019-08-26 US US16/550,342 patent/US11471410B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018504450A (ja) | 2018-02-15 |
| HUE062561T2 (hu) | 2023-11-28 |
| JP6836510B2 (ja) | 2021-03-03 |
| US10391058B2 (en) | 2019-08-27 |
| PL3229776T3 (pl) | 2023-11-06 |
| US20190374465A1 (en) | 2019-12-12 |
| LT3229776T (lt) | 2023-08-25 |
| US11471410B2 (en) | 2022-10-18 |
| DK3229776T3 (da) | 2023-07-31 |
| EP3229776B1 (en) | 2023-06-28 |
| FI3229776T3 (fi) | 2023-08-15 |
| TW201628654A (zh) | 2016-08-16 |
| PT3229776T (pt) | 2023-08-17 |
| US20170258717A1 (en) | 2017-09-14 |
| WO2016083343A1 (en) | 2016-06-02 |
| ES2951598T3 (es) | 2023-10-23 |
| EP3229776A1 (en) | 2017-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102781A1 (es) | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, su preparación y sus usos | |
| CL2018002787A1 (es) | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. | |
| WO2016011284A3 (en) | Methods and compositions comprising particles for use in oil and/or gas wells | |
| BR112017000800A8 (pt) | Tratamento do câncer com uma combinação de radiação, nanoparticulas de óxido de cério, e um agente quimioterápico | |
| MX2017009948A (es) | Adsorbentes zeoliticos de alta superficie externa, su procedimiento de preparacion y sus usos. | |
| WO2016086206A8 (en) | Probiotic compositions containing clostridiales for inhibiting inflammation | |
| CL2016002258A1 (es) | Una composición para el cuidado oral que comprende un carbonato de calcio tratado mediante reacción superficial | |
| AR102782A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| BR112017015008A2 (pt) | trilho | |
| WO2017132555A8 (en) | Alk polypeptides and methods of use thereof | |
| CL2019003293A1 (es) | Composiciones que comprenden derivados de naftiridina y adyuvante de aluminio para su uso en el tratamiento de tumores sólidos. | |
| AR102779A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| JP2018504450A5 (enExample) | ||
| MX371417B (es) | Composiciones de profarmacos de aripiprazol. | |
| MX391458B (es) | Carbonato de calcio precipitado, un metodo para su fabricacion y usos del mismo. | |
| CR20190131A (es) | 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
| CO2021002721A2 (es) | Suspensiones líquidas de paracetamol | |
| MX2018011016A (es) | Formulaciones estables para liofilizar particulas terapeuticas. | |
| WO2016015055A8 (en) | Colon cleansing compositions | |
| CL2017003350A1 (es) | Composiciones farmacéuticas sólidas para el tratamiento del vhc | |
| WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
| WO2016033549A3 (en) | (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE | |
| CY1121594T1 (el) | Συνθεσεις προφαρμακου αριπιπραζολης | |
| ES2526816B1 (es) | Composiciones para el tratamiento del daño hepático |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |